Provexis Plc

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00B0923P27
GBP
0.01
0 (12.5%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Sep 24

  • RAW MATERIAL COST(Y) Grown by 59.8% (YoY)
2

Risky -

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 14 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.55

stock-summary
Return on Equity

-34.89%

stock-summary
Price to Book

10.85

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.86%
0%
-14.86%
6 Months
23.53%
0%
23.53%
1 Year
-7.35%
0%
-7.35%
2 Years
26.0%
0%
26.0%
3 Years
-10.0%
0%
-10.0%
4 Years
-25.88%
0%
-25.88%
5 Years
-21.25%
0%
-21.25%

Provexis Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
14.17%
EBIT Growth (5y)
-0.20%
EBIT to Interest (avg)
-0.42
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.55
Tax Ratio
1.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
14.49
EV to EBIT
-14.01
EV to EBITDA
-14.01
EV to Capital Employed
14.01
EV to Sales
11.68
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-47.48%
ROE (Latest)
-48.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bullish
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Provexis Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2023 is 0.00% vs -20.00% in Mar 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2023 is -100.00% vs 50.00% in Mar 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'23",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.40",
          "val2": "-0.30",
          "chgp": "-33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.40",
          "val2": "-0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,122.20%",
          "val2": "-695.10%",
          "chgp": "-42.71%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Mar'23stock-summary
Mar'23
Mar'22
Change(%)
Net Sales
0.40
0.40
Operating Profit (PBDIT) excl Other Income
-0.40
-0.30
-33.33%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.40
-0.20
-100.00%
Operating Profit Margin (Excl OI)
-1,122.20%
-695.10%
-42.71%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2023 is 0.00% vs -20.00% in Mar 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2023 is -100.00% vs 50.00% in Mar 2022

stock-summaryCompany CV
About Provexis Plc stock-summary
stock-summary
Provexis Plc
Pharmaceuticals & Biotechnology
Provexis plc is engaged in developing and licensing the Fruitflow heart-health functional food ingredient for the global functional food sector. Fruitflow is a tomato extract, which inhibits platelet aggregation that causes heart attack, stroke and venous thrombosis. The syrup and powder versions of Fruitflow are used in foods, beverages and supplements. The powder version is used in a range of products, including soft gels, capsules, tablets and stick packs. The Company also offers Fruitflow + Omega-3 dietary supplement product, which is a two-in-one supplement in an easy to take capsule supporting healthy blood flow and normal heart function. Fruitflow + Omega-3 dietary supplement product is available through its e-commerce Website www.fruitflowplus.com. The Company's subsidiaries include Provexis Nutrition Limited, Provexis Natural Products Limited and Provexis (IBD) Limited, which are engaged in providing functional food, medical food and dietary supplement technologies.
Company Coordinates stock-summary
Company Details
2 Blagrave Street , READING None : RG1 1AZ
stock-summary
Tel: 44 1753 861777
stock-summary
Registrar Details